ADMA (ADMA Biologics) Cyclically Adjusted FCF per Share: $-0.99 (As of Mar. 2026)


ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.95
GF Value $18.00
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Cyclically Adjusted FCF per Share?

ADMA Biologics ADMA +3.95% 64 Cyclically Adjusted FCF per Share is $-0.99 as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.00 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ADMA Biologics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.232. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.99 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ADMA Biologics was 14.10% per year. The lowest was -6.10% per year. And the median was 6.05% per year.

As of today (2026-07-03), ADMA Biologics's current stock price is $8.95. ADMA Biologics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.99. ADMA Biologics's Cyclically Adjusted Price-to-FCF of today is .


ADMA Biologics  (NAS:ADMA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ADMA Biologics Cyclically Adjusted FCF per Share Related Terms


ADMA Biologics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Cyclically Adjusted FCF per Share Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.75 -1.67 -1.49 -1.24 -1.06

ADMA Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.21 -1.16 -1.13 -1.06 -0.99

ADMA vs ZLAB, HRMY, STOK: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, ADMA Biologics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Cyclically Adjusted Price-to-FCF falls into.


ADMA
64GF Score
ADMA Biologics Inc ADMA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ADMA Biologics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.232/330.2130*330.2130
=0.232

Current CPI (Mar. 2026) = 330.2130.

ADMA Biologics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.400 241.018 -0.548
201609 -0.364 241.428 -0.498
201612 -0.281 241.432 -0.384
201703 -0.419 243.801 -0.568
201706 -0.540 244.955 -0.728
201709 -0.400 246.819 -0.535
201712 -0.339 246.524 -0.454
201803 -0.375 249.554 -0.496
201806 -0.361 251.989 -0.473
201809 -0.276 252.439 -0.361
201812 -0.423 251.233 -0.556
201903 -0.311 254.202 -0.404
201906 -0.359 256.143 -0.463
201909 -0.432 256.759 -0.556
201912 -0.358 256.974 -0.460
202003 -0.362 258.115 -0.463
202006 -0.295 257.797 -0.378
202009 -0.305 260.280 -0.387
202012 -0.370 260.474 -0.469
202103 -0.310 264.877 -0.386
202106 -0.288 271.696 -0.350
202109 -0.121 274.310 -0.146
202112 -0.205 278.802 -0.243
202203 -0.147 287.504 -0.169
202206 -0.085 296.311 -0.095
202209 -0.085 296.808 -0.095
202212 -0.055 296.797 -0.061
202303 -0.075 301.836 -0.082
202306 -0.031 305.109 -0.034
202309 0.048 307.789 0.051
202312 0.072 306.746 0.078
202403 -0.019 312.332 -0.020
202406 0.179 314.175 0.188
202409 0.098 315.301 0.103
202412 0.191 315.605 0.200
202503 -0.100 319.799 -0.103
202506 0.075 322.561 0.077
202509 -0.004 324.800 -0.004
202512 0.141 324.054 0.144
202603 0.232 330.213 0.232

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.99 mean?
ADMA Biologics (ADMA) has a Cyclically Adjusted FCF per Share of $-0.99 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Cyclically Adjusted FCF per Share too high?
ADMA Biologics' current Cyclically Adjusted FCF per Share is $-0.99. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Cyclically Adjusted FCF per Share compare to ZLAB and HRMY?
ADMA Biologics' Cyclically Adjusted FCF per Share of $-0.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Cyclically Adjusted FCF per Share is $-0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.00, compared to a current price of $8.95 — trading 50.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.99. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Cyclically Adjusted FCF per Share is $-0.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.95 is trading 50.3% below its estimated GF Value™ of $18.00. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Cyclically Adjusted FCF per Share: $-0.99
  • GF Value™: $18.00 vs. price of $8.95 (50.3% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.95
Price
$18.00
GF Value